Graham T. Dempsey, Ph.D., is the Co-Founder and CEO of Quiver Bioscience, a Cambridge-based biotech company that is decoding neurons to unlock breakthrough CNS therapeutics. Graham is leading the Series A financing of Quiver to advance the company’s first products derived from their proprietary discovery platform to the clinic, including a non-opioid therapeutic for chronic pain and a disease-modifying precision medicine for a devastating neurodevelopmental disorder. Prior to this role, Graham served as the Chief Scientific Officer, directing the planning and execution of all scientific, medical, engineering and AI/machine learning activities at the company. Since the company’s inception, he successfully led the development and rapid evolution of the company’s technology platforms as well as its first small molecule and antisense oligonucleotide CNS therapeutic programs, leading to several foundational patents and peer-reviewed publications. Over this period, Graham also led more than a dozen pharma collaborations along with successful funding of >$30M in grants from non-dilutive funding sources such as the NIH SBIR Programs and CNS Foundations. He also serves on the Scientific Advisory Board of the Dan Lewis Foundation for Brain Regeneration Research and the editorial board of Molecular Therapy Nucleic Acids.

Graham holds a B.A. in biochemistry and biophysics from the University of Pennsylvania and a Ph.D. in biophysics from Harvard Medical School, where he co-invented novel, fluorescence-based imaging platforms for nanoscale investigation of biological systems, including super-resolution imaging (stochastic optical reconstruction microscopy or STORM) that was subsequently commercialized by Nikon Instruments.